 Aura Biosciences Inc NASDAQ: AURA reported data from a retrospective analysis that assessed the visual acuity after plaque radiotherapy treatment compared with prospective data in early-stage choroidal melanoma patients treated with belzupacap sarotalocan by intravitreal. 